Item
Newly discovered compounds for controlling blood sugar.
Executive Summary
A family of compounds, naturally occurring in sugarcane (Saccharum sp.), have been discovered. These compounds are effective at controlling blood sugar levels, and have the ability to be commercialised as:
> nutraceutical;
> complementary medicine;
> pharmaceutical.
Patent protection has been applied for: AU 2009901641.
Background
The Cooperative Research Centre for Sugar Industry Innovation through Biotechnology (CRC Sugar) is Australia's leading sugarcane industry research entity (www.crcsugar.com).
Hyperglycemia, a disorder which results in elevated and sustained blood sugar levels after a meal, is most commonly caused by the metabolic disorder: diabetes mellitus.
Acarbose (Bayer) is a leading synthetic anti-diabetes drug, which, when taken with a meal, inhibits the enzymes in the gut and α-amylase from the pancreas and in saliva.
Acarbose (FDA Application No. (NDA) 020 482) was approved for distribution on 6 September 1995.
The U.S. Food and Drug Administration advise that there is no therapeutic equivalent to Acarbose.
CRC Sugar has found compounds that occur naturally in sugarcane plants.
These compounds can be extracted from sugarcane waste, after commercial extraction of the sugar has been completed.
In laboratory trials of crude extract, the compounds discovered by CRC Sugar display activity up to 77 times greater than Acarbose in moderating enzymes and are three times more effective at moderating α-amylase.
When purified the compounds are up to fifty times more potent towards α-amylase than Acarbose.
These compounds are suitable for commercialisation as a nutraceutical, complementary medicine and/or a pharmaceutical.
The compounds are considered suitable candidates for GRAS classification by the U.S. Food and Drug Administration.
Preliminary work by the CRC Sugar indicates synthesis of the more potent compounds is commercially feasible.
Opportunity
CRC Sugar is seeking commercialisation partners in three major industry categories:
> nutraceutical/functional food and/or food additive;
> complementary medicines;
> pharmaceutical drug candidate.
Item
Newly discovered compounds for controlling blood sugar.
Executive Summary
A family of compounds, naturally occurring in sugarcane (Saccharum sp.), have been discovered. These compounds are effective at controlling blood sugar levels, and have the ability to be commercialised as:
> nutraceutical;
> complementary medicine;
> pharmaceutical.
Patent protection has been applied for: AU 2009901641.
Background
The Cooperative Research Centre for Sugar Industry Innovation through Biotechnology (CRC Sugar) is Australia's leading sugarcane industry research entity (www.crcsugar.com).
Hyperglycemia, a disorder which results in elevated and sustained blood sugar levels after a meal, is most commonly caused by the metabolic disorder: diabetes mellitus.
Acarbose (Bayer) is a leading synthetic anti-diabetes drug, which, when taken with a meal, inhibits the enzymes in the gut and α-amylase from the pancreas and in saliva.
Acarbose (FDA Application No. (NDA) 020 482) was approved for distribution on 6 September 1995.
The U.S. Food and Drug Administration advise that there is no therapeutic equivalent to Acarbose.
CRC Sugar has found compounds that occur naturally in sugarcane plants.
These compounds can be extracted from sugarcane waste, after commercial extraction of the sugar has been completed.
In laboratory trials of crude extract, the compounds discovered by CRC Sugar display activity up to 77 times greater than Acarbose in moderating enzymes and are three times more effective at moderating α-amylase.
When purified the compounds are up to fifty times more potent towards α-amylase than Acarbose.
These compounds are suitable for commercialisation as a nutraceutical, complementary medicine and/or a pharmaceutical.
The compounds are considered suitable candidates for GRAS classification by the U.S. Food and Drug Administration.
Preliminary work by the CRC Sugar indicates synthesis of the more potent compounds is commercially feasible.
Opportunity
CRC Sugar is seeking commercialisation partners in three major industry categories:
> nutraceutical/functional food and/or food additive;
> complementary medicines;
> pharmaceutical drug candidate.